For healthcare professionals. This information does not replace clinical judgement in the individual case; the current summary of product characteristics and the guidelines cited are authoritative.
Medically reviewed: Dr. med. univ. Daniel Pehböck, DESA, 01.11.2026
Esmolol (β1-selective beta blocker, ultra-short-acting (half-life approx. 9 min)) – indications: SVT, atrial fibrillation/flutter with rapid ventricular rate – rate control, Perioperative tachycardia and hypertension – immediate control. Weight-based dosing in mg and ml in the app, with sources.
Indications
- SVT, atrial fibrillation/flutter with rapid ventricular rate – rate control
- Perioperative tachycardia and hypertension – immediate control
Complete in the app
Weight-based doses in mg and ml, preparations, contraindications and notes – in the app, also offline.
Sources and guidelines
- Van Gelder IC, Rienstra M et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2024;45:3314–3414.
- Summaries of product characteristics of authorised products – product and section for each dose in the app.